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Abstract
Background: Type 2 diabetes is an important cause of morbidity and mortality. Its prevalence
appears to be increasing. Guidelines exist regarding its management. Recommendations regarding
drug therapy have changed. Little is known about the influence of these guidelines and changed
recommendations on the actual management of patients with type 2 diabetes. This study aims to
document trends in the prevalence, drug treatment and recording of measures related to the
management of type 2 diabetes; and to assess whether recommended targets can be met.
Methods: The population comprised subjects registered between 1994 and 2001 with 74 general
practices in England and Wales which routinely contribute to the Doctors' Independent Network
database. Approximately 500,000 patients and 10,000 type 2 diabetics were registered in each year.
Results: Type 2 diabetes prevalence rose from 17/1000 in 1994 to 25/1000 in 2001. Drug therapy
has changed: use of long acting sulphonylureas is falling while that of short acting sulphonylureas,
metformin and newer therapies including glitazones is increasing. Electronic recording of HbA1c,
blood pressure, cholesterol and weight have risen steadily, and improvements in control of blood
pressure and cholesterol levels have occurred. However, glycaemic control has not improved, and
obesity has increased. The percentage with a BMI under 25 kg/m2 fell from 27.0% in 1994 to 19.4%
in 2001 (p < 0.001).
Conclusion: Prevalence of type 2 diabetes is increasing. Its primary care management has changed
in accordance with best evidence. Monitoring has improved, but further improvement is possible.
Despite this, glycaemic control has not improved, while the prevalence of obesity in the diabetic
population is rising.
Background
Type 2 diabetes is a common condition with high morbid-
ity and mortality. Its diagnosis appears to be increasing [1-
3], probably reflecting an underlying rise in prevalence. In
many countries, guidelines for its management have been
issued [4-6], and in the United Kingdom (UK), these are
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reflected in the National Service Framework for Diabetes,
which sets national standards and defines service models
for the condition[7]. UK Family Practitioners' remunera-
tion will increasingly depend on hitting targets which
encompass both process of care and health related out-
comes[8]. In this context, process includes monitoring of
the disease and of modifiable risk factors that might lead
to complications. In particular, it is important to manage
cardiovascular risk in diabetics because diabetes acceler-
ates vascular occlusion and much of the excess mortality
is due to cardiovascular mortality[9].
Practitioners will be judged largely on the achievement of
target levels for the process measures monitored. Achiev-
ing such targets requires pharmacotherapy in most cases.
In recent years a number of new drugs for the manage-
ment of diabetes have appeared and research evidence
suggests that these should replace some older drugs and
supplement others, whilst some drugs, such as met-
formin, should be used more frequently [10-12].
In this study, we use routinely collected computer data to
examine trends in the prevalence of diagnosed Type 2 dia-
betes, the drug treatment of the condition and recording
of measurements utilised in its management, including
body mass index (BMI), blood pressure and glycosylated
haemoglobin (HbA1c). Finally we examine trends in the
achievement of management target levels for these meas-
urements as suggested by national guidance.
Methods
The Doctors' Independent Network (DIN) is an ano-
nymised, computerised UK primary care database com-
prising 142 Family Practices that we consider to be good
quality data providers[13]. Morbidity and drug data are
coded using Read codes (4 byte). This study uses data
from 74 practices that had continuous recording from
1994 to 2001, eliminating possible spurious trends
caused by having different practices in the sample over
time. We included patients in a given year if they
remained registered on 31st December of that year and for
6 months previously.
Diabetics were identified by electronically searching the
database for all diabetic Read codes. Diabetics on insulin
were classified as type I or type II based on an algorithm
(available from authors) which used date of diagnosis and
date of first being seen in the practice, in combination
with the timing of treatment with oral hypoglycaemics
(British National Formulary (BNF) section 6.1.2) and/or
insulin (BNF section 6.1.1). The decision was largely
straightforward for diabetics newly diagnosed while they
were registered with practices using their electronic data-
base. Diabetics were classified as type 1 if a Read code
"Diabetes + ketoacidosis -no coma" was present or if insu-
lin was given within 90 days of first diagnosis. The prob-
lems arose for those diabetics diagnosed in the past who
were using insulin at the point of registration with the
practice or when the practice started using the electronic
database. While dates of first diagnosis were usually avail-
able, as were date of registration and first recording of
events within practice, we did not have information on
when insulin treatment was started prior to electronic
recording. In this instance it was necessary to base the
decision on the age of the patient at first diagnosis (≥35
years implies type 2) as well as the time lapse between
when the patient was first seen in the practice and when
an insulin prescription was issued (>180 days implies
type 2). Based on a random sample of 150 records of dia-
betics receiving insulin, the algorithm had 94% sensitivity
and 93% specificity for classifying type 2 diabetics com-
pared to blind assessment by a clinician (SDeW) of the
same electronic records. Type 2 diabetics were further clas-
sified by treatment received in a given year into: diet, oral
only, or insulin (with or without oral).
The records of Type 2 diabetics were searched for Read
codes for Body Mass Index (BMI), blood pressure, total
cholesterol, and glycosylated haemoglobin (HbA1c).
Read codes for these data may be indicative (e.g. "choles-
terol raised") or have a numerical value assigned. In ear-
lier years indicative codes tended to be used more, and for
HbA1c, these were the only recording option before 1997.
If an indicative code (or a biologically implausible numer-
ical code) was used then we counted the measurement as
having occurred, but set its value to be missing.
Where multiple measurements took place in a given year,
we used the last recorded measurement in that year.
Numerical values were selected in preference to indicative
codes even if they were not the last recorded measurement
in a year. BMI values were supplemented by weight
records, if an existing height measurement was present in
the record, allowing BMI to be calculated.
In order to examine trends in the achievement of manage-
ment targets, data were compared with targets set in guid-
ance published by the National Institute for Clinical
Excellence (NICE). The NICE targets are: BMI <25 kg/m2,
blood pressure <140/80 mmHg or <160/100 mmHg
depending on coronary event risk, HbA1c <6.5% or
<7.5% depending on coronary event risk, and total cho-
lesterol <5 mmol/l[4,5]. No target figure is set for smoking
reduction.
To test whether any trends in the achievement of manage-
ment targets were influenced by the improvements in the
recording of data, we restricted the analyses to 16 practices
with a consistently high level of recording and low levels
of missing values. To establish whether any trends in the
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percentage of diabetics meeting targets were due to differ-
ences in the way that newly diagnosed diabetics were
being managed, analyses were also repeated after restric-
tion to newly diagnosed diabetics.
Statistical methods
To adjust for the changing age structure of type 2 diabetics
between 1994–2001 we used the 2001 population of DIN
to age standardise prevalence rates using the direct
method. Descriptive analyses of practice variation in
recording of risk factor data (Figure 3) are summarised
using box and whisker plots using the SAS procedure
BOXPLOT (SAS Institute Inc., North Carolina, USA). Tests
for trend across years are based on fitting the logit of the
percentage of diabetics in a practice with the relevant risk
factor recorded in a given year using SAS procedure
GENMOD.
Tests for trends of targets met across years was based on
individual data using a logit link adjusting for age, sex and
practice, which was included as a categorical variable with
74 levels. Year was fitted as a linear variable to test for
trend. The model was fitted using SAS procedure GEN-
MOD with a first order autoregressive structure to allow
for higher correlation of measurements on the same indi-
viduals when measured in adjacent years.
In order to assess whether changes in HbA1c over years
were influenced by the changes in BMI, we regressed the
recorded HbA1c levels on age, sex, practice and year
Distribution of the practice percentage of diabetics with a risk factor measured by yearFigure 3
Distribution of the practice percentage of diabetics with a risk factor measured by year. – Boxes indicate the 
median, lower and upper quartiles Whiskers extend to the practice immediately proceeding 1.5 times the interquartile range 
from the median. Practices lying outside this range are individually plotted. – % of all measurements that were numeric and 
valid were for each risk factor: BMI (95%), Blood Pressure (97%), HbA1c (61%) and Cholesterol (91%).
(a) Body Mass Index (b) Blood Pressure
(c) HbA1c (d) Cholesterol
BMC Family Practice 2005, 6:13 http://www.biomedcentral.com/1471-2296/6/13
Page 4 of 8
(page number not for citation purposes)
before further including BMI. Various models were fitted
using the SAS procedure MIXED, allowing us to take
account of individuals contributing data to variable num-
bers of years.
Results
Diabetes prevalence trends
The population totalled approximately half a million
patients annually (Table 1). Between 1994 and 2001, the
prevalence of diagnosed Type 2 diabetes increased stead-
ily, rising from 18 to 27 per 1000 in men and from 16 to
23 per 1000 in women. The age standardised rates (Table
1) were almost identical. In both sexes, the most notable
increases were in the 65–74 age group (men increased
from 68 to 101 per 1000, women from 47 to 73 per
1000).
Trends in therapy
During the 1990's there were steady increases in the prev-
alence of diet only, oral treatment only and insulin treated
Table 1: Prevalence rates (per 1000) of type 2 diabetics from the DIN database (74 practices)
1994 1995 1996 1997 1998 1999 2000 2001
Total males 237,872 239,427 243,618 251,005 255,833 259,670 260,383 262,290
- Diet controlled only 1,689 1,788 1,830 1,940 1,971 2,086 2,218 2,285
- On oral drug only 2,111 2,186 2,374 2,573 2,833 3,128 3,417 3,779
- On insulin 542 569 637 704 785 894 985 1,052
Total type 2 diabetics 4,342 4,543 4,841 5,217 5,589 6,108 6,620 7,116
0–34 years 1 1 1 1 1 1 1 1
35–44 7 7 7 8 8 8 9 9
45–54 18 18 19 21 22 23 26 27
55–64 45 47 49 50 52 54 56 57
65–74 69 71 75 79 85 91 96 101
75–84 72 78 77 82 86 94 99 109
85+ 79 72 74 72 71 77 81 89
Crude overall rate 18 19 20 21 22 23 25 27
Age Std Rate* 19 20 21 22 23 24 26 27
95% CI 18–21 19–21 20–22 21–23 22–24 23–25 25–27 26–28
Total females 241,995 242,996 246,885 253,383 258,695 262,241 263,475 264,763
- Diet controlled only 1,404 1,496 1,565 1,658 1,722 1,791 1,885 2,065
- On oral drug only 1,824 1,915 2,070 2,244 2,427 2,586 2,844 3,048
- On insulin 528 532 579 632 712 801 888 941
Total type 2 diabetics 3,756 3,943 4,214 4,534 4,861 5,178 5,617 6,057
0–34 years 1 1 1 1 1 2 2 2
35–44 6 6 6 7 7 8 9 9
45–54 12 13 14 15 15 16 17 19
55–64 33 34 34 34 36 38 38 40
65–74 47 50 53 59 63 66 70 73
75–84 53 56 59 59 61 67 72 76
85+ 48 48 53 52 56 58 61 68
Crude overall rate 16 16 17 18 19 20 21 23
Age Std Rate* 16 17 17 18 19 20 22 23
95% CI 15–17 16–18 16–19 17–19 18–20 19–21 21–23 22–24
* - Age standardised rate is made to the 2001 DIN Population
Prevalence of type 2 diabetic treatment groups in the DIN database over timeFigur  1
Prevalence of type 2 diabetic treatment groups in 
the DIN database over time. Blue – On insulin, Red – On 
oral drug only, Green – Diet controlled only
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type 2 diabetes (Figure 1). However, the proportion of
type 2 diabetics treated by diet alone fell between 1994
and 2001 (from 38.2% to 33.0%), while those treated
with any insulin (13.2% to 15.1%) and oral agents only
(48.6% to 51.8%) both increased.
Trends in oral therapy are shown in Figure 2. Use of ultra-
long acting sulphonylureas had almost completely ceased
by 2001 when it was received by 0.1% of diabetics. The
use of long acting sulphonylureas and guar gum (0.2% in
1994 to 0.04% in 2001 – not shown in Figure 2) has also
reduced. In contrast, the use of short acting sulphonylu-
reas increased (from 23.3% to 35.1%), as did the use of
metformin (from 22.6% to 38.9%). The use of the intesti-
nal alpha glucosidase inhibitor, acarbose, increased up to
1999, rising from 1.7% in 1994 to 3.8% in 1999, then
declined back to 2.4% in 2001. Thiazolidinediones and
meglitinides started being used in the final years of the
study.
Recording of indicators of process of care
Trends in recording of measurements linked to the proc-
ess of diabetic care where targets are set in NICE guidance
are shown in Figure 3. Recording of all measures has
increased (P < 0.001), especially the recording of HbA1c
(practice median 34 % in 1994 to 74% in 2001) and cho-
lesterol (practice median 17% in 1994, 61% in 2001). The
practice median for recording of BMI was 43% of patients
in 1994 rising to 55% in 2001; for blood pressure it rose
from 65% in 1994 to 82% in 2001. Less than 10% of all
measurements made were classified as "missing" for all
except HbA1c. For HbA1c 39% of measurements recorded
as being made were "missing" due to the sole existence of
indicative codes before 1997. There was variation in
recording between practices in any given year which,
while it diminished over time, was still marked in 2001,
with one practice still not recording any of the measures.
Outcomes: achievement of national quality targets
Trends in the percentage of diabetics whose management
achieved NICE targets are shown in Figure 4. There has
been a marked increase (P < 0.001) in the percentage of
diabetics with a total cholesterol <5 mmol/l. (46.2% in
2001), and a steady increase in patients with blood pres-
sure readings below the target levels (P < 0.001), although
only 22.5% had a blood pressure less than 140/80 in
2001.
The percentage of patients meeting either of the target
HbA1c figures has however tended to fall, except for 2001
when there was a small increase (trend tests P < 0.001 for
lower target, P = 0.14 for higher target) : 22.5% of patients
in 2001 had an HbA1c of less than 6.5% compared to
28.9% in 1997; 52.3% of patients in 2001 had an HbA1c
less than 7.5% compared to 53.7% in 1997. A steady fall
in the percentage of patients with a BMI less than 25 kg/
m2 has also occurred (P < 0.001) with 19.4% of patients
achieving this criterion in 2001, compared with 27.0% in
1994.
In order to assess whether the lack of improvement in glu-
cose control over time might be due to the steady increase
in the obesity of the diabetic population, we estimated the
Changes in the non-insulin treatment of type 2 diabetics over timeFigur  2
Changes in the non-insulin treatment of type 2 dia-
betics over time. Light Blue – Metformin, Red – Short act-
ing sulphonylurea, Green – Long acting acting sulphonylurea, 
Orange – Ultra long acting sulphonylurea, Purple – Acarbose, 
Yellow – Meglitinides, Dark Blue – Thiazolidinediones/Glita-
zones Footnote: Treatment groups are not mutually 
exclusive
(NICE/NSF) Risk factor targets achieved in all type 2 diabet-ics by yearFigure 4
(NICE/NSF) Risk factor targets achieved in all type 2 
diabetics by year. (Results are age & sex standardised to 
the 2001 population) Denominators are the number of sub-
jects with a valid numerical value recorded. HbA1C results 
start in 1997 as numerical codes could not be recorded prior 
to 1997.
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mean HbA1c levels adjusted for age, sex and practice and
then further adjusted for BMI. The mean levels unadjusted
for BMI reflected the same pattern as in figure 4; that is the
mean HbA1c rose from 7.73% in 1997 to 7.82% in 2000
before falling back to 7.69% in 2001. While BMI was
highly significantly related to HbA1c, adjustment for it
had little effect on the estimated HbA1c means for the dif-
ferent years.
Trends in practices with high levels of recording of target 
related data
When the above analyses were restricted to 16 practices
with consistently high levels of data recording (corre-
sponding to those above the upper quartile in Figure 3 for
each factor), the trends in meeting targets as described
above remained almost unaltered (data not shown).
Treatment of newly diagnosed diabetics
The trends in treatment and other management in newly
diagnosed diabetics were almost identical to those seen
for all diabetics (data not shown).
Discussion
Principal findings
This study confirms that the prevalence of all diagnosed
type 2 diabetes continues to rise. The data are consistent
with data published from the General Practice Research
Database (GPRD) to 1998[3]. However, that study failed
to identify diet treated diabetics or to include those type 2
diabetics treated with insulin. Our figures for overall prev-
alence and type of therapy amongst type 2 diabetics com-
pares well with the only other UK source we have
identified. In that much smaller study, the prevalence of
type 2 diabetes was 20.3 per 1000 in males and 16.7 per
1000 in females in 1997, of whom 34% were treated by
diet only, 53% were oral only and 14% were on insu-
lin[14]. It is reassuring that two studies based on very dif-
ferent methodologies give such similar results.
The prevalence of diabetes has risen steadily in developed
and developing countries throughout the second half of
the 20th century[1]. Rising levels of obesity in the general
population are believed to be one of the principal driv-
ers[1], and in a recent Danish study it was concluded that
the rise in diabetes between 1974/75 and 1996/97 was
entirely attributable to the concurrent rise in body mass
index[15]. It seems likely that this underlies the steady
increase we have observed, given that the percentage of
adult males in England with a BMI over 30 rose from
13.8% in 1994 to 21.0% in 2001 while for women the
trend was from 17.3% to 23.5% [16]. While there is a the-
oretical possibility that changes in the definition of
diabtetes introduced from 1998 on may have had some
effect, it seems likely to have been limited given that the
steady increase in the prevalence of type 2 diabetes pre-
dated the change in diagnostic criteria; in 1998–9 the def-
inition of diabetes shifted from those with a 2 hour post
load plasma glucose > 11.1 mmol/l or a fasting level ≥ 7.8
mmo//l to a fasting plasma glucose ≥ 7 mmol/l[17].
Family doctors have altered drug therapies in accordance
with research evidence and best guidance [10-12] and
have introduced new drugs as they become available. The
broad trends in therapy are consistent with published data
from the Prescription Pricing Authority[18], the advan-
tage being that our data are patient rather than prescrip-
tion based and also specific to type 2 diabetes.
Measurement and electronic recording of data of value in
the management of diabetes has steadily increased. The
only measurement not to show substantial improvement
and an increase to a high level of recording is the BMI. It
is not clear why this should be, but improvement could be
easily achieved. The steady improvement in data record-
ing predates the issue of national guidance and targets and
implies that doctors have improved care through the
assimilation of best evidence without the need for other
inducements.
It has recently been suggested that quality of data record-
ing is not a valid indicator of quality of care[19] and,
notwithstanding improvements in monitoring and in
drug therapy, it is striking to note that glycaemic control
has not improved over the period of observation. This is
paralleled by a decrease in the percentage of patients
achieving a BMI of <25 kg/m2. The increasing weight of
the diabetic population reflects the general increase in
weight of the UK population[20], but also may reflect the
tendency for many diabetic medications to produce
weight gain as an unwanted effect. Data from the US sug-
gest that obesity is rising in newly diagnosed diabetics and
that this is associated with poorer prognosis[21]. It is
ironic that BMI is the least well recorded measure in this
study.
It is tempting to conclude that the lack of improvement in
HbA1c control is attributable to the increasing obesity of
the diabetic population. However, our analyses of this
suggest that the increase in BMI amongst diabetics only
had a small effect on the observed HbA1c levels. Further
investigation of this issue is certainly warranted, but the
statistical analysis is complicated due to the unbalanced
data whereby individuals contribute varying numbers of
observations, while data recording standards are changing
over time, raising the possibility that missing observations
are not random. It would also be important to distinguish
between changes in BMI as a result of diabetic therapies,
and the increasing BMI of the general population.
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Other targets in diabetic care are increasingly being met,
especially in the area of lipid control. Increased use of
drug therapy probably accounts for this and mirrors the
increased use of lipid lowering therapy in secondary pre-
vention of ischaemic heart disease[22]. Blood pressure
control has improved but is a long way from meeting the
lower targets for most patients as suggested by guid-
ance[4]. This may again be consequent on the increasing
obesity of the diabetic population and suggests that blood
pressure targets in general practice populations may be
very difficult to achieve. It should also be noted that blood
pressure target levels in UK guidance are rather modest
compared to those in US guidance[6].
In contrast to our findings, a recent Swedish study, based
on a national diabetes register, reported improvements in
HbA1c, as well as in blood pressure levels and increased
use of statins, between 1996 and 1999; the Swedish study
also reported rising BMI levels [23]. A Dutch study [24]
reported similar improvements in blood pressure and
cholesterol levels between 1993 and 1999. However, that
study also showed improvements in HbA1c. No data on
obesity were presented.
Finally, when assessing targets it is important to recognise
that complete success is unrealistic. Some patients who
comply will not respond to treatment, others will opt-out
of treatment, while for others with major co-morbidities
the GP may choose not to treat [24]. Further work to
assess the realistic target achievable would be worthwhile.
Limitations of the study
Our study only reflects what was recorded on the compu-
ter systems. It seems reasonable to focus on such data
given that these are increasingly being used for monitor-
ing performance in achieving targets. However, it is
important to consider whether a rising level of recording
or the changing population of diabetics might account for
the changes observed. As similar trends were seen in a sub-
set of practices that had always had high levels of record-
ing and low levels of missing values, it is unlikely that
rising levels of recording explain our observations. This is
consistent with the findings regarding data completeness
and quality of care previously alluded to[19]. Comparable
trends were also seen in new as well as established diabet-
ics and observed in the control of blood pressure and cho-
lesterol in patients with cardiovascular disease; suggesting
that there is consistent improvement in the control of
these risk factors.
With DIN, as with all primary care databases, it is impor-
tant to consider whether the prevalence of disease, record-
ing of risk factors and achievement of targets are
nationally representative. The age-sex structure of DIN is
identical to the UK average, but more practices are in the
south and lower socio-economic groups are under-repre-
sented[13]. Nevertheless we have demonstrated that
period prevalence rates for a wide range of diseases are
similar to those in GPRD[22,25], and this also holds for
diabetes (data not shown). There is also evidence that
research and non-research practices are similar in disease
outcomes[26]. It seems likely that levels of electronic risk
factor recording will be above average in an electronic
database, although many practices were still doing poorly.
While in theory higher levels of recording might improve
control of risk factors, there was no clear evidence of this
within DIN practices – at practice level there was no asso-
ciation between level of recording and the lower manage-
ment target for HbA1c (Pearson correlation = 0.07 in
2001). In summary we believe that the trends seen are typ-
ical of those seen nationally, though the overall level of
electronic recording is likely to be higher in DIN.
Conclusion
This study highlights the improvements in the process of
diabetic care that have been achieved in primary care
without the inducements of national targets. Despite this,
glycaemic control has not improved and obesity has
increased. While increasing obesity does not straightfor-
wardly explain why glycaemic control is not improving it
is of itself associated with worse prognosis[21]. Doctors
have limited power to affect the weight of their
patients[20], and unless weight control in the general
population becomes a matter of more importance in
national policy, it seems likely that the incidence of diabe-
tes will continue to rise while targets for diabetic control
will not be met in most patients.
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